NCT00882804 - Hemin in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Healthy Volunteers

Interventions

DRUG

Hemin infusion

Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in \~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.

DRUG

placebo infusion

25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.

Trial Locations (1)

55905

Mayo Clinic, Rochester